FCA Corp TX Sells 783 Shares of Stryker Corporation $SYK

Key Points

• FCA Corp TX decreased its stake in Stryker Corporation by 5.6% during the first quarter, owning 13,286 shares worth approximately $4.95 million.
• Stryker recently reported earnings of $3.13 per share for the last quarter, beating estimates, alongside a revenue of $6.02 billion, up 11.1% year-over-year.
• Insider transactions include Director Ronda E. Stryker selling 200,000 shares at an average price of $376.45, representing a 5.84% decrease in her ownership.

FCA Corp TX trimmed its position in Stryker Corporation (NYSE:SYK - Free Report) by 5.6% during the first quarter, according to its most recent 13F filing with the SEC. The fund owned 13,286 shares of the medical technology company's stock after selling 783 shares during the period. Stryker comprises approximately 1.6% of FCA Corp TX's holdings, making the stock its 13th largest holding. FCA Corp TX's holdings in Stryker were worth $4,946,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in SYK. Brighton Jones LLC boosted its position in shares of Stryker by 15.4% in the 4th quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company's stock worth $1,643,000 after purchasing an additional 609 shares during the last quarter. CreativeOne Wealth LLC boosted its position in shares of Stryker by 24.4% in the 4th quarter. CreativeOne Wealth LLC now owns 2,586 shares of the medical technology company's stock worth $931,000 after purchasing an additional 508 shares during the last quarter. Guggenheim Capital LLC boosted its position in shares of Stryker by 7.0% in the 4th quarter. Guggenheim Capital LLC now owns 7,579 shares of the medical technology company's stock worth $2,729,000 after purchasing an additional 499 shares during the last quarter. Jump Financial LLC bought a new position in shares of Stryker in the 4th quarter worth $4,204,000. Finally, Gamco Investors INC. ET AL boosted its position in shares of Stryker by 17.1% in the 4th quarter. Gamco Investors INC. ET AL now owns 21,568 shares of the medical technology company's stock worth $7,766,000 after purchasing an additional 3,150 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In related news, Director Ronda E. Stryker sold 200,000 shares of Stryker stock in a transaction dated Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total transaction of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares in the company, valued at approximately $1,212,962,556.60. This trade represents a 5.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 5.90% of the company's stock.

Stryker Stock Up 1.5%

Shares of NYSE SYK traded up $5.8040 during mid-day trading on Tuesday, hitting $387.4140. The company had a trading volume of 556,774 shares, compared to its average volume of 1,431,346. The company has a market capitalization of $148.11 billion, a PE ratio of 51.21, a price-to-earnings-growth ratio of 2.78 and a beta of 0.91. The firm has a 50-day simple moving average of $386.77 and a two-hundred day simple moving average of $379.38. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70. Stryker Corporation has a one year low of $329.16 and a one year high of $406.19.

Stryker (NYSE:SYK - Get Free Report) last announced its quarterly earnings data on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, beating the consensus estimate of $3.07 by $0.06. The company had revenue of $6.02 billion during the quarter, compared to analysts' expectations of $5.92 billion. Stryker had a return on equity of 23.94% and a net margin of 12.25%.Stryker's revenue for the quarter was up 11.1% compared to the same quarter last year. During the same quarter last year, the company earned $2.81 EPS. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, equities analysts expect that Stryker Corporation will post 13.47 EPS for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Investors of record on Tuesday, September 30th will be issued a dividend of $0.84 per share. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 dividend on an annualized basis and a yield of 0.9%. Stryker's dividend payout ratio (DPR) is presently 44.50%.

Wall Street Analysts Forecast Growth

Several analysts recently commented on SYK shares. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a research note on Monday, May 5th. BTIG Research reaffirmed a "buy" rating on shares of Stryker in a research note on Monday, July 14th. Truist Financial set a $415.00 price objective on Stryker and gave the stock a "hold" rating in a research note on Monday, August 4th. Needham & Company LLC raised their price objective on Stryker from $442.00 to $448.00 and gave the stock a "buy" rating in a research note on Friday, August 1st. Finally, Roth Mkm raised their price objective on Stryker from $405.00 to $456.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Fifteen research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $430.10.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.